Literature DB >> 6208142

Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens.

R R Kantor, A K Ng, P Giacomini, S Ferrone.   

Abstract

Reagents exchanged at the 2nd workshop on monoclonal antibodies (MoAb) to human melanoma antigens were analyzed using both serological and immunochemical assays. The analysis by laboratories participating in the workshop of our MoAb 225.28S, 345.134S, 376.96S, 465.12S, and 763.24TS reaffirms our own analysis of these reagents in that (1) they all react with the majority of melanoma cell lines tested and (2) the reactivity of MoAb 225.28S and 763.24TS is much more restricted than that of MoAb 345.134S 376.96S, and 465.12S. Our serological analysis revealed that the majority of workshop reagents reacted with cultured melanoma cells. Immunochemical analysis of these monoclonal antibodies allowed for their division into three groups according to the molecular weights of the antigens recognized in immunoprecipitation experiments, greater than 100 kd, 80-100 kd, and DR antigens. Further analysis of the first two groups of monoclonal antibodies by immunodepletion and antibody binding inhibition assays revealed that MoAb 9.2.27, 225.28S, and 763.24TS recognize distinct determinants with a heterogeneous distribution on subpopulations of a high molecular weight melanoma associated antigen. MoAb 376.96S and 705.F6 recognize either the same or spatially close determinant(s).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6208142     DOI: 10.1089/hyb.1.1982.1.473

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  7 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.

Authors:  P Garin-Chesa; H R Beresford; A Carrato-Mena; H F Oettgen; L J Old; M R Melamed; W J Rettig
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

4.  Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.

Authors:  Yuying Liu; Weihe Zhang; Ting Niu; Lawrence H Cheung; Anupama Munshi; Raymond E Meyn; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

5.  Monoclonal antibodies that prevent adhesion of B 16 melanoma cells and reduce metastases in mice: crossreaction with human tumor cells.

Authors:  H P Vollmers; W Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

6.  Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.

Authors:  A Godal; O Bruland; E Haug; M Aas; O Fodstad
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

7.  CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.

Authors:  Caitlin E Egan; Dessislava Stefanova; Adnan Ahmed; Vijay J Raja; Jessica W Thiesmeyer; Kevin J Chen; Jacques A Greenberg; Taotao Zhang; Bing He; Brendan M Finnerty; Rasa Zarnegar; Moonsoo M Jin; Theresa Scognamiglio; Noah Dephoure; Thomas Fahey; Irene M Min
Journal:  Thyroid       Date:  2021-07-05       Impact factor: 6.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.